Intended for use in patients with viral loads ≥500 copies/mL. HIV-1 combined pheno- and genotyping test to provide antiretroviral susceptibility information for protease inhibitors (PI) and reverse transcriptase inhibitors (ie, NRTI and NNRTI). Preferred test for patients with known or suspected complex drug resistance patterns (eg, suboptimal virologic response to treatment and viral load rebound).
Polymerase Chain Reaction (PCR)/Culture
New York DOH Approval Status
Lavender (EDTA) or Plasma Preparation Tube (PPT).
Separate from cells within 6 hours of collection. Transfer 3 mL plasma to an ARUP Standard Transport Tube and freeze immediately. (Min: 1 mL)
Test is not performed at ARUP; separate specimens must be submitted when multiple tests are ordered.
Provide patient's most recent viral load and viral load collection date.
Ambient: Unacceptable; Refrigerated: Unacceptable; Frozen: 2 weeks
Performed by non-ARUP Laboratory
Procedure should be used for patients with documented HIV-1 infection and viral loads greater than 500 copies/mL.
87900; 87901; 87903; 87904 x12
|Component Test Code*||Component Chart Name||LOINC|
|0092074||Viral Load Date||19151-0|
|2003232||EER HIV PhenoSense GT||11526-1|
- HIV Resistance